Date,Articles
2014-10-21,"{""abstract"": ""The hedge fund suggested that the drug maker should consider splitting itself up into a faster-growing entity whose products require research spending and a slower-growing company with more mature products."", ""web_url"": ""https://dealbook.nytimes.com/2014/10/21/third-point-loebs-hedge-fund-urges-amgen-to-consider-a-breakup/"", ""snippet"": ""The hedge fund suggested that the drug maker should consider splitting itself up into a faster-growing entity whose products require research spending and a slower-growing company with more mature products."", ""lead_paragraph"": ""With corporate breakups on Wall Street\u2019s mind, one of the biggest activist hedge fund managers around thinks the maneuver could prove helpful for the drug giant Amgen."", ""print_section"": ""B"", ""print_page"": ""7"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Third Point, Loeb\u2019s Hedge Fund, Urges Amgen to Consider a Breakup"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Breakup Urged"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Loeb, Daniel S"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Third Point LLC"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-10-21T20:03:43+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c6d2a5fd-aec2-5f83-9876-6cf785319308"", ""word_count"": 570, ""uri"": ""nyt://article/c6d2a5fd-aec2-5f83-9876-6cf785319308""}"
2014-10-22,"{""abstract"": ""The idea of a corporate split comes up often in the drug industry but rarely happens. But Amgen\u2019s drug focus and the banker background of its C.E.O. give the notion a chance, Robert Cyran of Reuters Breakingviews writes."", ""web_url"": ""https://dealbook.nytimes.com/2014/10/22/amgens-boss-makes-a-prime-target-for-a-breakup/"", ""snippet"": ""The idea of a corporate split comes up often in the drug industry but rarely happens. But Amgen\u2019s drug focus and the banker background of its C.E.O. give the notion a chance, Robert Cyran of Reuters Breakingviews writes."", ""lead_paragraph"": ""Amgen\u2019s boss makes a prime breakup target for Daniel S. Loeb. The chief executive, Robert Bradway, a former Morgan Stanley banker, has run the $109 billion biotechnology company for the last two years. The idea of splitting such companies into a cash cow and a growth arm comes up often, but rarely happens. Amgen may be the exception."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Amgen\u2019s Boss Makes a Prime Breakup Target for Loeb"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Biotechnology and Bioengineering"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Bradway, Robert A"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Loeb, Daniel S"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-10-22T15:46:26+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/363e6bcc-ba94-56e5-91c1-f71aceaf6684"", ""word_count"": 395, ""uri"": ""nyt://article/363e6bcc-ba94-56e5-91c1-f71aceaf6684""}"
2014-11-20,"{""abstract"": ""In the Another View column, Bill George examines four situations \u2014 Amgen, PepsiCo, DuPont, and Allergan \u2014 to see where activist investors have it wrong."", ""web_url"": ""https://dealbook.nytimes.com/2014/11/20/when-activist-investors-target-strong-companies/"", ""snippet"": ""In the Another View column, Bill George examines four situations \u2014 Amgen, PepsiCo, DuPont, and Allergan \u2014 to see where activist investors have it wrong."", ""lead_paragraph"": ""Bill George is a professor of management at Harvard Business School and a former chairman and chief executive of Medtronic."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/22/business/dbpix-pepsico/dbpix-pepsico-articleLarge.jpg"", ""height"": 397, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/11/22/business/dbpix-pepsico/dbpix-pepsico-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 397}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/22/business/dbpix-pepsico/dbpix-pepsico-jumbo.jpg"", ""height"": 677, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/22/business/dbpix-pepsico/dbpix-pepsico-superJumbo.jpg"", ""height"": 1354, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/22/business/dbpix-pepsico/dbpix-pepsico-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/11/22/business/dbpix-pepsico/dbpix-pepsico-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/22/business/dbpix-pepsico/dbpix-pepsico-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""When Activist Investors Aim at Strong Companies"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Shareholder Rights and Activism"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Ackman, William A"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Loeb, Daniel S"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Nooyi, Indra K"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Peltz, Nelson"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pyott, David E I"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Sharer, Kevin W"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""DuPont Co"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pepsico Inc"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2014-11-20T23:45:26+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Bill George"", ""person"": [{""firstname"": ""Bill"", ""middlename"": null, ""lastname"": ""George"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/87fde083-f3c9-5282-9631-36c8b45f1911"", ""word_count"": 874, ""uri"": ""nyt://article/87fde083-f3c9-5282-9631-36c8b45f1911""}"
2015-03-15,"{""abstract"": ""Researchers cautioned, however, that the studies were small and meant to assess whether the drugs safely lowered cholesterol, not whether they staved off heart attacks."", ""web_url"": ""https://www.nytimes.com/2015/03/16/business/tests-of-cholesterol-drugs-offer-hope-of-reducing-heart-attacks-and-strokes.html"", ""snippet"": ""Researchers cautioned, however, that the studies were small and meant to assess whether the drugs safely lowered cholesterol, not whether they staved off heart attacks."", ""lead_paragraph"": ""A new class of experimental cholesterol drugs might sharply reduce the risk of heart attacks and strokes, researchers reported on Sunday, citing what they described as preliminary evidence."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Tests of Cholesterol Drugs Offer Hope of Reducing Heart Attacks and Strokes"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Tests of Cholesterol Drugs Offer Hope of Reducing Heart Attacks and Strokes"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""New England Journal of Medicine"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Heart"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stroke"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Regeneron Pharmaceuticals Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sanofi SA"", ""rank"": 9, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Statins (Cholesterol-Lowering Drugs)"", ""rank"": 10, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Nissen, Steven E"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Cleveland Clinic"", ""rank"": 12, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Los Angeles (Calif)"", ""rank"": 13, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""San Diego (Calif)"", ""rank"": 14, ""major"": ""N""}], ""pub_date"": ""2015-03-15T15:54:35+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/6fa258ac-aa43-5fad-8a2e-73dafe509b43"", ""word_count"": 981, ""uri"": ""nyt://article/6fa258ac-aa43-5fad-8a2e-73dafe509b43""}"
2015-04-15,"{""abstract"": ""Many Wall Street analysts and heart specialists are lukewarm about the drug, which has shown mixed results in clinical trials."", ""web_url"": ""https://www.nytimes.com/2015/04/16/business/fda-approves-amgen-drug-to-treat-heart-failure.html"", ""snippet"": ""Many Wall Street analysts and heart specialists are lukewarm about the drug, which has shown mixed results in clinical trials."", ""lead_paragraph"": ""The Food and Drug Administration on Wednesday approved a drug to treat chronic heart failure that may help keep patients out of the hospital."", ""print_section"": ""A"", ""print_page"": ""19"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""F.D.A. Approves Amgen Drug to Treat Heart Failure"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""F.D.A. Approves Drug to Treat Heart"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Heart"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2015-04-15T22:17:19+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f288e090-b0e5-50e3-936d-956ac1f4ed06"", ""word_count"": 633, ""uri"": ""nyt://article/f288e090-b0e5-50e3-936d-956ac1f4ed06""}"
2015-08-27,"{""abstract"": ""The new drug is made by Amgen for people with extremely high cholesterol levels and heart patients who do not get adequate results from statins and other therapies."", ""web_url"": ""https://www.nytimes.com/2015/08/28/health/fda-approves-another-in-a-new-class-of-cholesterol-drugs.html"", ""snippet"": ""The new drug is made by Amgen for people with extremely high cholesterol levels and heart patients who do not get adequate results from statins and other therapies."", ""lead_paragraph"": ""The Food and Drug Administration on Thursday approved the second drug in a novel class of powerful cholesterol-lowering medications."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/08/28/science/28DRUG1/28DRUG1-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/08/28/science/28DRUG1/28DRUG1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/08/28/science/28DRUG1/28DRUG1-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/08/28/science/28DRUG1/28DRUG1-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/08/28/science/28DRUG1/28DRUG1-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/08/28/science/28DRUG1/28DRUG1-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/08/28/science/28DRUG1/28DRUG1-thumbLarge-v2.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""F.D.A. Approves Repatha, a Second Drug for Cholesterol in a Potent New Class"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""F.D.A. Approves the Second Drug for Cholesterol in a Potent New Class"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Kolata, Gina"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Repatha (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Heart"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2015-08-27T21:28:15+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Gina Kolata"", ""person"": [{""firstname"": ""Gina"", ""middlename"": null, ""lastname"": ""Kolata"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9b9bdba9-e905-531c-aebf-ed2c98b28128"", ""word_count"": 898, ""uri"": ""nyt://article/9b9bdba9-e905-531c-aebf-ed2c98b28128""}"
2015-09-08,"{""abstract"": ""A report from the Institute for Clinical and Economic Review says the prices on two drugs to fight cholesterol that cost more than $14,000 a year should be slashed."", ""web_url"": ""https://www.nytimes.com/2015/09/09/business/new-cholesterol-drugs-are-vastly-overpriced-analysis-says.html"", ""snippet"": ""A report from the Institute for Clinical and Economic Review says the prices on two drugs to fight cholesterol that cost more than $14,000 a year should be slashed."", ""lead_paragraph"": ""Two powerful new drugs that can sharply lower cholesterol are vastly overpriced based on the value they provide, according to a new analysis by an independent organization that evaluates pharmaceutical costs."", ""print_section"": ""A"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/09/09/business/09drug-web1/09drug-web1-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/09/09/business/09drug-web1/09drug-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/09/09/business/09drug-web1/09drug-web1-jumbo.jpg"", ""height"": 600, ""width"": 900, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/09/09/business/09drug-web1/09drug-web1-superJumbo.jpg"", ""height"": 600, ""width"": 900, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/09/09/business/09drug-web1/09drug-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/09/09/business/09drug-web1/09drug-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/09/09/business/09drug-web1/09drug-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""New Cholesterol Drugs Are Vastly Overpriced, Analysis Says"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""New Cholesterol Drugs Are Overpriced, Analysis Finds"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Institute for Clinical and Economic Review"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sanofi SA"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Prices (Fares, Fees and Rates)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Praluent (Drug)"", ""rank"": 9, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Repatha (Drug)"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2015-09-08T21:24:28+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3341e2ca-33ad-5fb4-8f9f-8a5b0d271d2a"", ""word_count"": 825, ""uri"": ""nyt://article/3341e2ca-33ad-5fb4-8f9f-8a5b0d271d2a""}"
2015-10-06,"{""abstract"": ""Rather than bargain with a single maker, the pharmacy benefits manager says it will offer both Repatha and Praluent, promising but expensive products."", ""web_url"": ""https://www.nytimes.com/2015/10/07/business/express-scripts-says-it-will-cover-2-new-cholesterol-drugs.html"", ""snippet"": ""Rather than bargain with a single maker, the pharmacy benefits manager says it will offer both Repatha and Praluent, promising but expensive products."", ""lead_paragraph"": ""The nation\u2019s largest manager of drug prescriptions said on Tuesday that it would pay for two drugs in a promising new class of cholesterol-lowering medicines, rather than choose one over the other in an effort to lower costs."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Express Scripts Says It Will Cover 2 New Cholesterol Drugs"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Express Scripts Will Cover 2 New Cholesterol Drugs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Express Scripts Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Repatha (Drug)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Praluent (Drug)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sanofi SA"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Gilead Sciences Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Regeneron Pharmaceuticals Inc"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2015-10-06T21:00:42+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1d43e58f-d265-5687-8309-22251685ed46"", ""word_count"": 772, ""uri"": ""nyt://article/1d43e58f-d265-5687-8309-22251685ed46""}"
2016-01-11,"{""abstract"": ""Some pharmaceutical companies will form the National Immunotherapy Coalition to rapidly test various combinations of promising new types of cancer drugs."", ""web_url"": ""https://www.nytimes.com/2016/01/12/business/drug-companies-to-try-a-unified-front-against-cancer.html"", ""snippet"": ""Some pharmaceutical companies will form the National Immunotherapy Coalition to rapidly test various combinations of promising new types of cancer drugs."", ""lead_paragraph"": ""SAN FRANCISCO \u2014 Some leading pharmaceutical companies are joining forces in an effort to speed the testing of new types of cancer drugs that harness the body\u2019s immune system to battle tumors."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-articleLarge.jpg"", ""height"": 419, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 419}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-jumbo.jpg"", ""height"": 716, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-superJumbo.jpg"", ""height"": 1432, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Drug Companies to Try a Unified Front Against Cancer"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Soon-Shiong, Patrick"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Celgene Corporation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2016-01-11T15:46:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e37fcae4-ae54-52e9-923d-774b4b8ee48f"", ""word_count"": 505, ""uri"": ""nyt://article/e37fcae4-ae54-52e9-923d-774b4b8ee48f""}"
2016-05-12,"{""abstract"": ""The blood-testing company, which is under criminal investigation, is replacing its chief operating officer and expanding its board."", ""web_url"": ""https://www.nytimes.com/2016/05/12/business/embattled-blood-lab-theranos-makes-a-bid-to-regain-confidence.html"", ""snippet"": ""The blood-testing company, which is under criminal investigation, is replacing its chief operating officer and expanding its board."", ""lead_paragraph"": ""In the latest attempt to restore confidence in its business, the embattled Silicon Valley blood-testing company Theranos is replacing its chief operating officer and expanding its board, including the addition of a former senior Amgen executive."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/12/business/12THERANOS/12THERANOS-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/05/12/business/12THERANOS/12THERANOS-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/12/business/12THERANOS/12THERANOS-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/12/business/12THERANOS/12THERANOS-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/12/business/12THERANOS/12THERANOS-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/05/12/business/12THERANOS/12THERANOS-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/12/business/12THERANOS/12THERANOS-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Embattled Blood Lab Theranos Makes a Bid to Regain Confidence"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Blood-Test Start-Up Takes Steps to Regain Confidence"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Theranos Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Abelson, Reed"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Balwani, Sunny"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tests (Medical)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Blood"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Holmes, Elizabeth (1984- )"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Appointments and Executive Changes"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2016-05-12T00:04:38+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Reed Abelson"", ""person"": [{""firstname"": ""Reed"", ""middlename"": null, ""lastname"": ""Abelson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ed25ecbc-1fd6-50dc-b442-caf8346491df"", ""word_count"": 700, ""uri"": ""nyt://article/ed25ecbc-1fd6-50dc-b442-caf8346491df""}"
2016-07-15,"{""abstract"": ""Six years after the Affordable Care Act cleared the way for biosimilars, as the generic versions of biotechnology drugs are called, progress has been slow."", ""web_url"": ""https://www.nytimes.com/2016/07/16/business/makers-of-humira-and-enbrel-using-new-drug-patents-to-delay-generic-versions.html"", ""snippet"": ""Six years after the Affordable Care Act cleared the way for biosimilars, as the generic versions of biotechnology drugs are called, progress has been slow."", ""lead_paragraph"": ""The best-selling drugs Humira and Enbrel have a lot in common. They both use biotechnology to treat rheumatoid arthritis, psoriasis and other autoimmune diseases. And they come with giant price tags approaching $50,000 a year."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/07/16/business/16DRUG-1/16DRUG-1-articleLarge.jpg"", ""height"": 851, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/07/16/business/16DRUG-1/16DRUG-1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 851}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/07/16/business/16DRUG-1/16DRUG-1-jumbo.jpg"", ""height"": 1024, ""width"": 723, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/07/16/business/16DRUG-1/16DRUG-1-superJumbo.jpg"", ""height"": 2048, ""width"": 1445, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/07/16/business/16DRUG-1/16DRUG-1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/07/16/business/16DRUG-1/16DRUG-1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/07/16/business/16DRUG-1/16DRUG-1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Makers of Humira and Enbrel Using New Drug Patents to Delay Generic Versions"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""New Patents Aim to Delay Generics of Biologics"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Biotechnology and Bioengineering"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic Brands and Products"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Prices (Fares, Fees and Rates)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Patient Protection and Affordable Care Act (2010)"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2016-07-15T23:45:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/781638b3-86bb-550c-94a0-d9f71db0317e"", ""word_count"": 1057, ""uri"": ""nyt://article/781638b3-86bb-550c-94a0-d9f71db0317e""}"
2016-11-08,"{""abstract"": ""Intensifying pressure stands to upend business models heavily dependent on raising prices."", ""web_url"": ""https://www.nytimes.com/2016/11/09/business/dealbook/valeants-struggles-are-a-bad-omen-for-the-entire-industry.html"", ""snippet"": ""Intensifying pressure stands to upend business models heavily dependent on raising prices."", ""lead_paragraph"": ""A disastrous quarter for Valeant Pharmaceuticals is a bad sign of things to come for a whole industry."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Valeant\u2019s Struggles Are a Bad Omen for the Entire Industry"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Valeant Pharmaceuticals International Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMERISOURCEBERGEN CORP"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Endo International PLC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Express Scripts Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2016-11-08T18:38:54+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/05a6aa58-e683-5ca1-b0a1-07c71db79a5b"", ""word_count"": 381, ""uri"": ""nyt://article/05a6aa58-e683-5ca1-b0a1-07c71db79a5b""}"
